4DMedical Shares Deliver Mighty 47% Four Day Rally

4DMedical shares (ASX:4DX) have staged a mighty four-day rally, climbing 47% from support at A$3.20 to close at A$4.72, as markets reassess the medical imaging company’s growth trajectory following a period of post-capital raise volatility.

The 4DX share price closed the most recent session up 9.77%, marking its fourth consecutive day of gains and pushing the stock back toward resistance levels seen during the June bounce. The RSI has climbed to 68.24, signalling strong momentum, and approaching overbought territory as the share price tests a technical zone that previously capped advances following the company’s regulatory milestones and ASX 200 inclusion.

Volatile Year For 4DX Holders

The sharp rebound follows a turbulent period for 4DMedical, which saw shares slide 29% in the month of July after markets digested the implications of a substantial A$150 million capital raise. That institutional bookbuild, led by Bell Potter, came on the back of an exceptional 2025 in which the stock surged more than 800% following FDA clearance for its flagship CT:VQ lung imaging technology and a significant licensing agreement with Koninklijke Philips NV.

CT:VQ, which uses advanced computed tomography to assess ventilation and perfusion in the lungs without radioactive tracers, has now secured regulatory approval across multiple jurisdictions. The technology holds FDA 510(k) clearance in the United States, CE Mark certification for the European Union, and Therapeutic Goods Administration approval in Australia. Additional submissions and clearances are progressing in Canada, the United Kingdom, New Zealand, and Brazil, expanding the addressable market for the company’s growing suite of respiratory and lung imaging products.

Clinical adoption has gained traction at prestigious institutions, with CT:VQ deployed at Mayo Clinic, and across multiple leading US academic medical centres. The company has also announced a major contract with SimonMed Imaging, one of the largest outpatient radiology providers in the United States, alongside the launch of the CLEAR clinical study to further validate the technology’s utility in pulmonary embolism diagnosis and lung function assessment.

Markets appear to be recalibrating their view on 4DMedical’s risk-reward profile, with the recent bounce suggesting that the post-raise selloff was more technical in nature than a fundamental reassessment of the company’s commercialisation pathway. The A$150 million cash injection has effectively removed near-term funding concerns, providing runway for the company to execute its multi-region rollout and integrate the contextflow acquisition without the need for additional dilutive capital in the immediate term.

What Next?

Technical traders are now watching the A$4.70 to A$4.80 zone closely, as this area provided resistance in June when TGA approval was being priced into the stock. A clean break above this level on sustained volume could open the door to a retest of the year’s highs, while a rejection would likely see consolidation or a pullback toward the A$4.00 psychological support level.

With a fully funded balance sheet, a growing regulatory footprint, and partnerships with major players in medical imaging and healthcare delivery, 4DMedical has assembled the building blocks for a significant commercial opportunity. There remains plenty for bears to remain interested, yet the short sellers that had been piling in prior the run-up may think twice about trying again after such a sharp reversal.